Wells Fargo Maintains Overweight on Enovis, Lowers Price Target to $39

Benzinga Newsdesk www.benzinga.com Negative 70.5%

Neg 70.5% Neu 0% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains Enovis (NYSE:ENOV) with a Overweight and lowers the price target from $40 to $39.